214 related articles for article (PubMed ID: 24895178)
1. Safety signal detection: the relevance of literature review.
Pontes H; Clément M; Rollason V
Drug Saf; 2014 Jul; 37(7):471-9. PubMed ID: 24895178
[TBL] [Abstract][Full Text] [Related]
2. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
4. A review of the National pharmacovigilance system in Malta - implementing and operating a pharmacovigilance management system.
Tanti A; Micallef B; Serracino-Inglott A; Borg JJ
Expert Opin Drug Saf; 2017 Jan; 16(1):65-76. PubMed ID: 27732110
[TBL] [Abstract][Full Text] [Related]
5. The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions.
Prescrire Int; 2015 Feb; 24(157):50-4. PubMed ID: 25802924
[TBL] [Abstract][Full Text] [Related]
6. EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies.
Francescon S; Fornasier G; Baldo P
Int J Clin Pharm; 2018 Aug; 40(4):778-782. PubMed ID: 30094558
[TBL] [Abstract][Full Text] [Related]
7. Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works.
Santoro A; Genov G; Spooner A; Raine J; Arlett P
Drug Saf; 2017 Oct; 40(10):855-869. PubMed ID: 28735357
[TBL] [Abstract][Full Text] [Related]
8. Pharmacovigilance in China: development and challenges.
Zhao Y; Wang T; Li G; Sun S
Int J Clin Pharm; 2018 Aug; 40(4):823-831. PubMed ID: 30051225
[TBL] [Abstract][Full Text] [Related]
9. The Importance of Direct Patient Reporting of Adverse Drug Reactions in the Safety Monitoring Process.
Sienkiewicz K; Burzyńska M; Rydlewska-Liszkowska I; Sienkiewicz J; Gaszyńska E
Int J Environ Res Public Health; 2021 Dec; 19(1):. PubMed ID: 35010673
[TBL] [Abstract][Full Text] [Related]
10. Enhancing Pharmacovigilance Capabilities in the EU Regulatory Network: The SCOPE Joint Action.
Radecka A; Loughlin L; Foy M; de Ferraz Guimaraes MV; Sarinic VM; Di Giusti MD; Lesicar M; Straus S; Montero D; Pallos J; Ivanovic J; Raine J
Drug Saf; 2018 Dec; 41(12):1285-1302. PubMed ID: 30128638
[TBL] [Abstract][Full Text] [Related]
11. Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology.
Baldo P; Francescon S; Fornasier G
Int J Clin Pharm; 2018 Aug; 40(4):748-753. PubMed ID: 30094557
[TBL] [Abstract][Full Text] [Related]
12. Overview of pharmacovigilance practices at the largest academic healthcare system in the State of Qatar.
Al Hail M; Elkassem W; Hamad A; Abdulrouf P; Thomas B; Stewart D
Int J Clin Pharm; 2018 Aug; 40(4):769-774. PubMed ID: 29616393
[TBL] [Abstract][Full Text] [Related]
13. Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre.
Watson S; Chandler RE; Taavola H; Härmark L; Grundmark B; Zekarias A; Star K; van Hunsel F
Drug Saf; 2018 Feb; 41(2):203-212. PubMed ID: 28933055
[TBL] [Abstract][Full Text] [Related]
14. Safety of medicines-Pharmacists' knowledge, practice, and attitudes toward pharmacovigilance and adverse drug reactions reporting process.
Kopciuch D; Zaprutko T; Paczkowska A; Ratajczak P; Zielińska-Tomczak Ł; Kus K; Nowakowska E
Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1543-1551. PubMed ID: 31148344
[TBL] [Abstract][Full Text] [Related]
15. Adverse drug reactions reporting in Calabria (Southern Italy) in the four-year period 2011-2014: impact of a regional pharmacovigilance project in light of the new European Legislation.
Leporini C; Marrazzo G; Mumoli L; Esposito S; Gallelli L; Mangano G; Brancati G; De Francesco EA; Russo E; De Sarro G;
Expert Opin Drug Saf; 2017 May; 16(5):515-522. PubMed ID: 28395523
[TBL] [Abstract][Full Text] [Related]
16. Improving the Safety of Medicines in the European Union: From Signals to Action.
Potts J; Genov G; Segec A; Raine J; Straus S; Arlett P
Clin Pharmacol Ther; 2020 Mar; 107(3):521-529. PubMed ID: 31621897
[TBL] [Abstract][Full Text] [Related]
17. Patient-Reported Safety Information: A Renaissance of Pharmacovigilance?
Härmark L; Raine J; Leufkens H; Edwards IR; Moretti U; Sarinic VM; Kant A
Drug Saf; 2016 Oct; 39(10):883-90. PubMed ID: 27379887
[TBL] [Abstract][Full Text] [Related]
18. Patient Reporting in the EU: Analysis of EudraVigilance Data.
Banovac M; Candore G; Slattery J; Houÿez F; Haerry D; Genov G; Arlett P
Drug Saf; 2017 Jul; 40(7):629-645. PubMed ID: 28417320
[TBL] [Abstract][Full Text] [Related]
19. Impact of Changing Regulations and the Dynamic Nature of European Risk Management Plans for Human Medicines on the Lifecycle of Safety Concerns.
Holm JEJ; Ruppert JG; Ramsden SD
Pharmaceut Med; 2022 Feb; 36(1):33-46. PubMed ID: 35099785
[TBL] [Abstract][Full Text] [Related]
20. Towards early detection of adverse drug reactions: combining pre-clinical drug structures and post-market safety reports.
Liu R; Zhang P
BMC Med Inform Decis Mak; 2019 Dec; 19(1):279. PubMed ID: 31849321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
